Qie Y, Huang S, Shen C, Wu Z, et al. Phase 2 pilot trial of tislelizumab plus low-dose nab-paclitaxel for extensive very high-risk non-muscle-invasive bladder cancer. Clin Cancer Res 2025 Jan 7. doi: 10.1158/1078-0432.CCR-24-3321.
PMID: 39777450